60 Degrees Pharmaceuticals (SXTP) Net Cash Flow (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Net Cash Flow of $1.8 million for Q1 2026, up 1.09% year-over-year from $1.8 million in Q1 2025, and up 169.95% quarter-over-quarter from -$2.6 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Net Cash Flow (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Net Cash Flow for 5 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 1.09% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at -$136713.0 (down 124.18% YoY), while the FY2025 annual figure was -$156415.0, up 67.66% from the prior year.
- Net Cash Flow grew to $1.8 million in Q1 2026 per SXTP's latest filing, from -$2.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $2.2 million in Q3 2023 and bottomed at -$2.6 million in Q4 2025.
- Historically, Net Cash Flow has averaged $166572.2 across 5 years, with a median of -$130230.0 in 2023.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 816.57% — and 2024, when it tumbled 12409.58%.
- 60 Degrees Pharmaceuticals' Net Cash Flow stood at -$193251.0 in 2022, then surged by 32.61% to -$130230.0 in 2023, then tumbled by 1158.81% to -$1.6 million in 2024, then plunged by 58.86% to -$2.6 million in 2025, then soared by 169.95% to $1.8 million in 2026.
- Business Quant data shows SXTP's Net Cash Flow at $1.8 million in Q1 2026, -$2.6 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 225.59 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.82 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | -2.60 Mn |
| Dec 31, 2025 | -2.60 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | -1.50 Mn |
| Jun 30, 2025 | -1.50 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | -1.32 Mn |
| Jun 30, 2024 | -1.32 Mn |
| Mar 31, 2024 | 753,039.00 |
| Mar 31, 2024 | 753,039.00 |
| Dec 31, 2023 | -130,230.00 |
| Dec 31, 2023 | -130,230.00 |